利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

90 条记录 (耗时 0.049 秒)

    Lactic acid bacteria of the Genus lactobacillus
    66.
    发明授权
    Lactic acid bacteria of the Genus lactobacillus 失效
    乳酸杆菌属的乳酸菌

    公开(公告)号：US5707854A

    公开(公告)日：1998-01-13

    申请号：US579573

    申请日：1995-12-27

    申请人： Yoshio Saito ,  Jun Mizutani

    发明人： Yoshio Saito ,  Jun Mizutani

    IPC分类号： C12N1/20 ,  A61K31/00 ,  A61K35/74 ,  A61P3/00 ,  A61P3/06 ,  C12N1/00 ,  C12N1/04 ,  C12R1/23

    CPC分类号： C12R1/225 ,  C12R1/23 ,  Y10S435/822 ,  Y10S435/854

    摘要： Lactic acid bacteria of the genus Lactobacillus do not exhibit deconjugation of bile acids and inhibition of nutrient absorption, and exhibit lowering of cholesterol in blood and liver. The particular species of the genus Lactobacillus exhibiting these characteristics is Lactobacillus acidophilus. Furthermore, the strain Lactobacillus acidophilus CL-0062 has been internationally deposited under accession number FERM BP-4980.

    摘要翻译： 乳酸杆菌属的乳酸菌不显示胆汁酸的脱羧和营养吸收的抑制，并显示血液和肝脏中的胆固醇降低。 表现出这些特征的乳杆菌属的具体种类是嗜酸乳杆菌（Lactobacillus acidophilus）。 此外，嗜酸乳杆菌CL-0062的菌株已经以保藏号FERM BP-4980进行国际保藏。

    Lactobacillus johnsonii ferm bp-2680 lactic acid bacteria preparations using the same and a process of manufacturing the preparations
    68.
    发明授权
    Lactobacillus johnsonii ferm bp-2680 lactic acid bacteria preparations using the same and a process of manufacturing the preparations 失效
    使用相同的约翰逊乳杆菌ferm bp-2680乳酸菌制剂及其制备方法

    公开(公告)号：US5296221A

    公开(公告)日：1994-03-22

    申请号：US51274

    申请日：1993-04-23

    申请人： Tomotari Mitsuoka ,  Kazumasa Suzuki ,  Mitsugu Hayashi ,  Umeyuki Doi ,  Tsuneo Hadeishi

    发明人： Tomotari Mitsuoka ,  Kazumasa Suzuki ,  Mitsugu Hayashi ,  Umeyuki Doi ,  Tsuneo Hadeishi

    IPC分类号： C12P7/56 ,  A61K37/00 ,  C12N1/00 ,  C12N1/20

    CPC分类号： C12R1/23 ,  C12P7/56 ,  Y10S435/853

    摘要： The present invention comprises a novel strain of Lactobacillus johnsonni FERM BP-2680, a lactic acid bacteria preparation using the Lactobacillus johnsonni FERM BP-2680, and a process of manufacturing the lactic acid bacteria preparation. The process includes the steps of inoculating the Lactobacillus johnsonni FERM BP-2680 into a medium containing fermentable sugar as a major carbon source, cultivating and proliferating under cultivation conditions adapted to anaerobes or facultative anaerobes, and further isolating the Lactobacillus johnsonni from the medium and drying the isolated Lactobacillus johnsonni with a protective agent to produce the lactic acid bacteria preparation. Optionally a bulking agent may be added to control cell concentration of the preparation. The preparation containing Lactobacillus johnsonni FERM BP-2680 is used to suppress harmful bacteria in the digestive tract of mammals.

    摘要翻译： 本发明包括新型的约氏乳杆菌FERM BP-2680菌株，使用约氏乳杆菌FERM BP-2680的乳酸菌制剂和制备乳酸菌制剂的方法。 该方法包括以下步骤：将约翰逊乳杆菌FERM BP-2680接种到含有可发酵糖作为主要碳源的培养基中，在适合于厌氧菌或兼性厌氧菌的培养条件下培养和增殖，并进一步从培养基中分离出约氏乳杆菌 分离的约氏乳杆菌用保护剂制备乳酸菌制剂。 任选地，可以加入填充剂以控制制剂的细胞浓度。 含有Lactobacillus johnsonni FERM BP-2680的制剂用于抑制哺乳动物消化道中的有害细菌。

    LACTIC ACID BACTERIAL STRAINS
    70.
    发明申请
    LACTIC ACID BACTERIAL STRAINS 审中-公开

    公开(公告)号：US20190216865A1

    公开(公告)日：2019-07-18

    申请号：US16206250

    申请日：2018-11-30

    申请人： 4D Pharma Research Limited

    发明人： Denise KELLY

    IPC分类号： A61K35/747 ,  A23L33/135 ,  A23K10/18 ,  C12R1/25 ,  C12R1/225 ,  C12R1/23 ,  C12N1/20

    CPC分类号： A61K35/747 ,  A23K10/18 ,  A23L33/135 ,  A23V2002/00 ,  C12N1/20 ,  C12R1/225 ,  C12R1/23 ,  C12R1/25 ,  Y02A50/473 ,  Y02A50/481

    摘要： A first aspect of the invention relates to a porcine lactic acid bacterial strain, wherein said bacterial strain is characterised by one or more of the following characteristics: (i) the ability to exhibit antimicrobial activity against E. coli; (ii) the ability to exhibit antimicrobial activity against S. enteritidis; (iii) the ability to suppress inflammation in IPEC cells induced by 12-0-tetradecaboylphorbol-13-acetate (PMA); (iv) the ability to block the attachment or invasion of IPEC cells by S. enteritidis; (v) the ability to block the attachment or invasion of IPEC cells by E. coli; (vi) the absence of antibiotic resistance to one or more antibiotics selected from the following: ampicillin; cefotaxime; chloramphenicol; erythromycin; gentamicin; tetracycline; vancomycin; metronizadole; nalidixic acid; and kanamycin; and (vii) the ability to exhibit heat stability when subjected to three cycles of heating, each cycle comprising heating at a temperature of 70° C. for a period of 15 minutes. Further aspects of the invention relate to compositions comprising said bacterial strains, and therapeutic uses of said bacterial strains.